According to national guidelines, all non-squamous NSCLC tumors should be tested for EGFR-, ALK-, and ROS1-alterations since the corresponding inhibitors became available at public hospitals in our country (8). The gene discussed is ALK; the disease is non-small cell lung carcinoma.